DiaGen AI  /  Pipeline

Programs advancing with named partners.

Assets move from generative design into partner wet labs. The KRAS oncology catalog is furthest along and available for partnering today, with IP retained in full by DiaGen.

AreaProgramPartner
DesignWet-labPre-clinicalPartnering
Oncology
DGEN1-5 KRAS catalogPancreatic & colorectal cancer
UNC — Structural Genomics Consortium
Peptide therapeutics
Three co-development projectsToward commercialization
Hadassah — Hadasit / Ariel University
Radiopharma
Radiopharma co-development
Hadassah — Hadasit / Ariel University
Longevity diagnostics
CRP biosensor · L.I.V.E.Continuous biochemical monitoring
University lab — under NDA
Discovery tooling
Multi-objective hit-picking toolNovelty, affinity, target specificity
MetaNova Labs — Bittensor SN68
Small molecule Peptide Scope being defined

Lead asset

DGEN1-5 KRAS catalog.

A joint AI and wet-lab collaboration with UNC's Structural Genomics Consortium targeting KRAS-driven cancers, with experimental validation led by Dr. Alison Axtman. DiaGen supplies AI-generated peptide and degrader libraries; UNC-SGC leads biological testing on open-science infrastructure.

Initial degrader molecules perform as expected in cells, degrading mutant KRAS — a target long considered undruggable.

Asset
DGEN1-5 KRAS catalog
AI-generated peptide and degrader libraries
Oncology
Indication
Pancreatic & colorectal cancer
KRAS-driven tumours
—
Stage
Pre-clinical
In-cell degradation confirmed
Validated
Status
Available for partnering
Open to pharma and biotech counterparties
Open
IP
Retained in full by DiaGen
Rights held as the catalog advances
Retained
Enquire about partnering →

Tech-Bio Partnering: Tools and Deployment

For platform access, catalog partnering or co-development enquiries.

IR@diagen.ai